

(1) Consolidated Profit and Loss Statement

Amounts less than the indicated unit are rounded down.

|                        |      | FYE March 2018 | FYE March 2019 | FYE March 2020 | FYE March 2021 | FYE March 2022 | FYE March 2023 |        |        |        |         | FYE March 2024 |        |      |         |        |        |       | 2024/3期               |                       |                      |
|------------------------|------|----------------|----------------|----------------|----------------|----------------|----------------|--------|--------|--------|---------|----------------|--------|------|---------|--------|--------|-------|-----------------------|-----------------------|----------------------|
|                        |      | FY2017         | FY2018         | FY2019         | FY2020         | FY2021         | FY2022         |        |        |        |         | FY2023         |        |      |         |        |        |       | FY2023                |                       |                      |
|                        |      | Full YR        | Full YR        | Full YR        | Full YR        | Full YR        | 1Q             | 2Q     | 3Q     | 4Q     | Full YR | 1Q             | 2Q     |      |         | 2Q-YTD |        |       | 2Q-YTD                | Full YR               | Full YR              |
|                        |      | A              | A              | A              | A              | A              | A              | A      | A      | A      | A       | A              | A      | YoY  | %       | A      | YoY    | %     | E(Prev) <sup>*1</sup> | E(Prev) <sup>*1</sup> | E(Rev) <sup>*2</sup> |
| Net Sales              | ¥mln | 42,298         | 45,525         | 51,761         | 51,286         | 51,469         | 12,969         | 12,519 | 13,009 | 13,251 | 51,750  | 12,954         | 12,177 | -342 | -2.7    | 25,132 | -356   | -1.4  | 23,880                | 48,807                | 50,680               |
| (Net Sales YoY)        | %    | 13.8           | 7.6            | 13.7           | -0.9           | 0.4            | 2.8            | 0.0    | -6.3   | 6.4    | 0.5     | -0.1           | -2.7   |      |         | -1.4   |        |       | -6.3                  | -5.7                  | -2.1                 |
| Cost of Goods Sold     | ¥mln | 15,722         | 17,703         | 22,570         | 22,622         | 22,634         | 5,510          | 5,432  | 5,415  | 5,497  | 21,855  | 5,066          | 4,834  | -597 | -11.0   | 9,900  | -1,041 | -9.5  | 9,459                 | 19,115                | 19,948               |
| Gross Profit           | ¥mln | 26,576         | 27,822         | 29,191         | 28,664         | 28,835         | 7,458          | 7,087  | 7,594  | 7,754  | 29,895  | 7,887          | 7,343  | 255  | 3.6     | 15,231 | 684    | 4.7   | 14,420                | 29,691                | 30,731               |
| Gross Margin           | %    | 62.8           | 61.1           | 56.4           | 55.9           | 56.0           | 57.5           | 56.6   | 58.4   | 58.5   | 57.8    | 60.9           | 60.3   |      |         | 60.6   |        |       | 60.4                  | 60.8                  | 60.6                 |
| SG&A Expenses          | ¥mln | 15,904         | 17,295         | 18,756         | 18,296         | 18,861         | 4,751          | 4,675  | 4,782  | 4,848  | 19,057  | 4,711          | 5,046  | 371  | 7.9     | 9,758  | 331    | 3.5   | 9,932                 | 19,927                | 19,786               |
| Operating Profit       | ¥mln | 10,671         | 10,526         | 10,434         | 10,367         | 9,973          | 2,707          | 2,412  | 2,811  | 2,906  | 10,837  | 3,176          | 2,296  | -115 | -4.8    | 5,472  | 353    | 6.9   | 4,488                 | 9,763                 | 10,945               |
| (Operating Profit YoY) | %    | 13.8           | -1.4           | -0.9           | -0.6           | -3.8           | 16.7           | 2.1    | -0.4   | 17.7   | 8.7     | 17.3           | -4.8   |      |         | 6.9    |        |       | -12.3                 | -9.9                  | 1.0                  |
| Operating Margin       | %    | 25.2           | 23.1           | 20.2           | 20.2           | 19.4           | 20.9           | 19.3   | 21.6   | 21.9   | 20.9    | 24.5           | 18.9   |      |         | 21.8   |        |       | 18.8                  | 20.0                  | 21.6                 |
| Non-Operating Income   | ¥mln | 259            | 571            | 891            | 1,031          | 316            | 72             | 122    | -16    | 114    | 293     | 132            | 121    | -1   | -0.9    | 254    | 59     | 30.5  | 72                    | 147                   | 335                  |
| Non-Operating Expenses | ¥mln | 200            | 289            | 900            | 879            | 285            | 105            | 96     | 16     | 6      | 224     | 65             | 39     | -56  | -58.5   | 105    | -96    | -47.8 | 61                    | 379                   | 436                  |
| Ordinary Profit        | ¥mln | 10,730         | 10,808         | 10,425         | 10,519         | 10,005         | 2,674          | 2,438  | 2,778  | 3,014  | 10,905  | 3,244          | 2,377  | -60  | -2.5    | 5,621  | 508    | 10.0  | 4,499                 | 9,531                 | 10,844               |
| Ordinary Margin        | %    | 25.4           | 23.7           | 20.1           | 20.5           | 19.4           | 20.6           | 19.5   | 21.4   | 22.7   | 21.1    | 25.0           | 19.5   | 0.0  | 0.0     | 22.4   | 0.0    | 0.0   | 18.8                  | 19.5                  | 21.4                 |
| Extraordinary Profit   | ¥mln | 1              | 5              | 3              | 3              | 44             | 1              | 0      | 0      | 98     | 100     | 0              | 12     | 11   | 1,649.1 | 12     | 10     | 518.9 | —                     | —                     | 12                   |
| Extraordinary Loss     | ¥mln | 116            | 12             | 4              | 5,982          | 8              | 5              | 0      | 1,194  | 16     | 1,217   | 4              | 4      | 3    | 782.6   | 8      | 2      | 37.0  | —                     | 4                     | 12                   |
| Net Profit Before Tax  | ¥mln | 10,615         | 10,801         | 10,425         | 4,540          | 10,041         | 2,670          | 2,438  | 1,583  | 3,096  | 9,789   | 3,240          | 2,386  | -52  | -2.1    | 5,626  | 517    | 10.1  | 4,499                 | 9,527                 | 10,845               |
| Tax Expenses           | ¥mln | 3,137          | 3,077          | 2,676          | 2,540          | 2,556          | 724            | 682    | 714    | 775    | 2,897   | 910            | 682    | 0    | 0.1     | 1,592  | 185    | 13.2  | 1,263                 | 2,673                 | 2,942                |
| Net Profit             | ¥mln | 7,478          | 7,723          | 7,748          | 2,000          | 7,484          | 1,946          | 1,756  | 869    | 2,320  | 6,891   | 2,330          | 1,703  | -52  | -3.0    | 4,033  | 331    | 9.0   | 3,235                 | 6,854                 | 7,902                |
| Net Profit %           | %    | 17.7           | 17.0           | 15.0           | 3.9            | 14.5           | 15.0           | 14.0   | 6.7    | 17.5   | 13.3    | 18.0           | 14.0   |      |         | 16.0   |        |       | 13.5                  | 14.0                  | 15.6                 |
| In-house Sales Ratio   | %    | 55.4           | 54.9           | 50.7           | 49.9           | 52.4           | 54.6           | 53.2   | 55.3   | 56.5   | 54.9    | 59.8           | 58.4   |      |         | 59.1   |        |       | —                     | 60.4                  | 59.6                 |
| R&D Expenses           | ¥mln | 1,121          | 1,431          | 1,743          | 1,667          | 2,159          | 547            | 583    | 576    | 607    | 2,316   | 502            | 576    | -7   | -1.2    | 1,078  | -52    | -4.7  | 1,077                 | 2,238                 | —                    |
| Capital Expenditure    | ¥mln | 3,630          | 1,248          | 2,536          | 1,382          | 1,633          | —              | —      | —      | —      | 976     | —              | —      | —    | —       | —      | —      | —     | —                     | 3,128                 | —                    |
| Depreciation Expenses  | ¥mln | 953            | 1,176          | 1,264          | 1,525          | 1,611          | 373            | 351    | 443    | 397    | 1,566   | 330            | 340    | -10  | -3.0    | 670    | -53    | -7.4  | 765                   | 1,603                 | —                    |

\*1 Disclosed on May 10, 2023  
\*2 Disclosed on Nobemver 6, 2023

(2) Consolidated Balance Sheet

Amounts less than the indicated unit are rounded down.

|                                        |      | FYE March 2018 | FYE March 2019 | FYE March 2020 | FYE March 2021 | FYE March 2022 | FYE March 2023 |        |        |         |  | FYE March 2024 |        |                     |        |  | 2024/3期 |         |         |
|----------------------------------------|------|----------------|----------------|----------------|----------------|----------------|----------------|--------|--------|---------|--|----------------|--------|---------------------|--------|--|---------|---------|---------|
|                                        |      | FY2017         | FY2018         | FY2019         | FY2020         | FY2021         | FY2022         |        |        |         |  | FY2023         |        |                     |        |  | FY2023  |         |         |
|                                        |      | Full YR        | Full YR        | Full YR        | Full YR        | Full YR        | 1Q             | 2Q     | 3Q     | 4Q      |  | 1Q             | 2Q     | vs<br>FY2022<br>End | %      |  | 2Q-YTD  | Full-YR | Full-YR |
|                                        |      | A              | A              | A              | A              | A              | A              | A      | A      | A       |  | A              | A      |                     |        |  | E(Prev) | E(Prev) | E(Rev)  |
| Current Assets                         | ¥mln | 40,821         | 41,665         | 44,077         | 44,522         | 45,153         | 40,481         | 41,918 | 43,243 | 47,130  |  | 42,989         | 40,941 | -6,188              | -13.1  |  | —       | —       | —       |
| Tangible Fixed Assets                  | ¥mln | 9,914          | 9,920          | 11,341         | 13,111         | 12,911         | 12,935         | 12,978 | 12,849 | 12,452  |  | 12,354         | 12,386 | -66                 | -0.5   |  | —       | —       | —       |
| Intangible Fixed Assets                | ¥mln | 576            | 558            | 493            | 505            | 1,470          | 1,723          | 2,102  | 2,230  | 2,414   |  | 2,482          | 2,480  | 66                  | 2.7    |  | —       | —       | —       |
| Investments and Others                 | ¥mln | 9,668          | 15,638         | 19,089         | 14,822         | 13,662         | 13,789         | 14,375 | 12,542 | 12,643  |  | 13,495         | 13,741 | 1,098               | 8.7    |  | —       | —       | —       |
| Fixed Assets                           | ¥mln | 20,159         | 26,117         | 30,923         | 28,439         | 28,044         | 28,449         | 29,455 | 27,622 | 27,510  |  | 28,332         | 28,608 | 1,098               | 4.0    |  | —       | —       | —       |
| Total Assets                           | ¥mln | 60,980         | 67,783         | 75,000         | 72,962         | 73,197         | 68,930         | 71,373 | 70,865 | 74,641  |  | 71,322         | 69,550 | -5,090              | -6.8   |  | —       | —       | —       |
| Current Liabilities                    | ¥mln | 15,452         | 14,580         | 16,093         | 16,467         | 14,211         | 12,970         | 13,570 | 12,498 | 14,381  |  | 12,392         | 12,279 | -2,102              | -14.6  |  | —       | —       | —       |
| Long-term Liabilities                  | ¥mln | 4,438          | 6,709          | 7,500          | 5,190          | 4,418          | 4,301          | 4,214  | 4,193  | 4,063   |  | 3,948          | 1,769  | -2,294              | -56.5  |  | —       | —       | —       |
| Total Liabilities                      | ¥mln | 19,890         | 21,289         | 23,594         | 21,657         | 18,629         | 17,272         | 17,785 | 16,692 | 18,445  |  | 16,340         | 14,048 | -4,397              | -23.8  |  | —       | —       | —       |
| Shareholder's Equity                   | ¥mln | 41,088         | 46,496         | 51,618         | 51,267         | 54,362         | 51,361         | 53,075 | 53,944 | 56,265  |  | 54,943         | 55,417 | -847                | -1.5   |  | —       | —       | —       |
| Accumulated other comprehensive income | ¥mln | -11            | -16            | -211           | 37             | 205            | 297            | 512    | 228    | -69     |  | 38             | 85     | 154                 | -223.1 |  | —       | —       | —       |
| Share Warrant                          | ¥mln | 13             | 13             | —              | —              | —              | —              | —      | —      | —       |  | —              | —      | —                   | —      |  | —       | —       | —       |
| Net Assets                             | ¥mln | 41,090         | 46,493         | 51,406         | 51,304         | 54,567         | 51,658         | 53,588 | 54,173 | 56,195  |  | 54,981         | 55,502 | -693                | -1.2   |  | —       | —       | —       |
| Total Liabilities and Net Assets       | ¥mln | 60,980         | 67,783         | 75,000         | 72,962         | 73,197         | 68,930         | 71,373 | 70,865 | 74,641  |  | 71,322         | 69,550 | -5,090              | -6.8   |  | —       | —       | —       |
| Cash and Deposits                      | ¥mln | 6,732          | 8,018          | 9,555          | 13,708         | 16,058         | 11,229         | 14,126 | 14,776 | 18,357  |  | 13,934         | 11,584 | -6,772              | -36.9  |  | —       | —       | —       |
| Accounts Receivables                   | ¥mln | 12,331         | 12,178         | 13,762         | 13,145         | 12,437         | 13,132         | 12,649 | 13,362 | 13,223  |  | 13,073         | 12,755 | -468                | -3.5   |  | —       | —       | —       |
| Inventory                              | ¥mln | 13,579         | 17,071         | 18,187         | 15,987         | 14,850         | 14,201         | 13,713 | 13,742 | 13,142  |  | 13,157         | 13,764 | 621                 | 4.7    |  | —       | —       | —       |
| Accounts Payables                      | ¥mln | 2,278          | 3,087          | 4,081          | 2,872          | 3,287          | 3,203          | 3,093  | 3,128  | 3,429   |  | 3,092          | 3,449  | 19                  | 0.6    |  | —       | —       | —       |
| Retained Earnings                      | ¥mln | 25,091         | 30,499         | 35,912         | 35,352         | 38,890         | 37,795         | 39,551 | 40,420 | 42,741  |  | 42,106         | 43,809 | 1,068               | 2.5    |  | —       | —       | —       |
| Interest-Bearing Debt                  | ¥mln | 9,396          | 9,987          | 11,538         | 10,396         | 8,352          | 7,679          | 7,331  | 7,140  | 6,883   |  | 6,637          | 4,668  | -2,214              | -32.2  |  | —       | —       | —       |
| Net Debt                               | ¥mln | 2,663          | 1,968          | 1,983          | -3,311         | -7,705         | -3,550         | -6,794 | -7,636 | -11,473 |  | -7,297         | -6,916 | 4,557               | -39.7  |  | —       | —       | —       |
| Invested Capital <sup>*1</sup>         | ¥mln | 50,484         | 56,484         | 63,156         | 61,663         | 62,714         | 59,041         | 60,407 | 61,085 | 63,148  |  | 61,580         | 60,085 | -3,062              | -4.9   |  | —       | —       | —       |
| Working Capital <sup>*2</sup>          | ¥mln | 23,632         | 26,161         | 27,868         | 26,260         | 24,000         | 24,130         | 23,268 | 23,976 | 22,937  |  | 23,137         | 23,070 | 133                 | 0.6    |  | —       | —       | —       |

\*1 A sum of interest-bearing debt and shareholder's equity  
\*2 Accounts receivables + Inventory - Accounts payables

(3) Consolidated Cash Flows

Amounts less than the indicated unit are rounded down.

|                                            |      | FYE March 2018 | FYE March 2019 | FYE March 2020 | FYE March 2021 | FYE March 2022 | FYE March 2023 |  |  |  |         | FYE March 2024 |  |  |  |        | 2024/3期 |         |         |
|--------------------------------------------|------|----------------|----------------|----------------|----------------|----------------|----------------|--|--|--|---------|----------------|--|--|--|--------|---------|---------|---------|
|                                            |      | FY2017         | FY2018         | FY2019         | FY2020         | FY2021         | FY2022         |  |  |  |         | FY2023         |  |  |  |        | FY2023  |         |         |
|                                            |      | Full YR        | Full YR        | Full YR        | Full YR        | Full YR        |                |  |  |  | Full YR |                |  |  |  | 2Q-YTD | 2Q-YTD  | Full-YR | Full-YR |
|                                            |      | A              | A              | A              | A              | A              |                |  |  |  | A       |                |  |  |  | A      | E(Prev) | E(Prev) | E(Rev)  |
| Operating Cash Flows                       | ¥mln | 4,450          | 7,037          | 7,096          | 11,432         | 10,246         |                |  |  |  | 11,201  |                |  |  |  | 1,873  | —       | —       | —       |
| Investing Cash Flows                       | ¥mln | -9,161         | -9,964         | -4,419         | -3,731         | -1,131         |                |  |  |  | -2,461  |                |  |  |  | -1,770 | —       | —       | —       |
| Financing Cash Flows                       | ¥mln | 11,294         | -1,783         | -1,136         | -3,720         | -6,804         |                |  |  |  | -6,476  |                |  |  |  | -6,884 | —       | —       | —       |
| Others                                     | ¥mln | 1              | -3             | -4             | 172            | 38             |                |  |  |  | 35      |                |  |  |  | 8      | —       | —       | —       |
| Net change in cash and cash equivalents    | ¥mln | 6,584          | -4,713         | 1,536          | 4,153          | 2,349          |                |  |  |  | 2,298   |                |  |  |  | -6,772 | —       | —       | —       |
| Cash and cash equivalents at end of period | ¥mln | 12,732         | 8,018          | 9,555          | 13,708         | 16,058         |                |  |  |  | 18,357  |                |  |  |  | 11,584 | —       | —       | —       |

(4) Financial Indicators etc.

Amounts less than the indicated unit are rounded down.

|                                                                             |        | FYE March 2018 | FYE March 2019 | FYE March 2020 | FYE March 2021 | FYE March 2022 | FYE March 2023 |                  |        |        |         | FYE March 2024 |        |  |        |  | 2024/3期 |         |         |
|-----------------------------------------------------------------------------|--------|----------------|----------------|----------------|----------------|----------------|----------------|------------------|--------|--------|---------|----------------|--------|--|--------|--|---------|---------|---------|
|                                                                             |        | FY2017         | FY2018         | FY2019         | FY2020         | FY2021         | FY2022         |                  |        |        |         | FY2023         |        |  |        |  | FY2023  |         |         |
|                                                                             |        | Full YR        | Full YR        | Full YR        | Full YR        | Full YR        | 1Q             | 2Q <sup>*7</sup> | 3Q     | 4Q     | Full-YR | 1Q             | 2Q     |  | 2Q-YTD |  | 2Q-YTD  | Full-YR | Full-YR |
|                                                                             |        | A              | A              | A              | A              | A              | A              | A                | A      | A      | A       | A              | A      |  | A      |  | E(Prev) | E(Prev) | E(Rev)  |
| Number of Shares Outstanding at Year-End (incl. treasury shares)            | K      | 90,419         | 90,419         | 85,419         | 85,419         | 85,419         | 85,419         | 82,919           | 82,919 | 82,919 | 82,919  | 82,919         | 82,919 |  | 82,919 |  | —       | —       | —       |
| Number of Treasury Shares at Year-End <sup>*1</sup>                         | K      | 10,005         | 10,005         | 5,165          | 5,050          | 5,500          | 7,453          | 4,999            | 4,999  | 4,999  | 4,999   | 5,653          | 6,837  |  | 6,837  |  | —       | —       | —       |
| Average Number of Shares During the FY(excl. treasury shares) <sup>*2</sup> | K      | 75,914         | 80,414         | 80,251         | 80,322         | 80,367         | 78,704         | 77,920           | 77,920 | 77,920 | 78,116  | 77,603         | 76,320 |  | 76,962 |  | —       | —       | —       |
| EPS <sup>*3</sup>                                                           | ¥      | 98.51          | 96.05          | 96.55          | 24.91          | 93.13          | 24.73          | 22.54            | 11.16  | 29.78  | 88.22   | 30.03          | 22.32  |  | 52.41  |  | 41.17   | 89.13   | 103.81  |
| BPS                                                                         | ¥      | 510.81         | 578.01         | 640.54         | 638.36         | 682.79         | 662.57         | 687.73           | 695.24 | 721.20 | 721.20  | 711.58         | 729.50 |  | 729.50 |  | —       | —       | —       |
| DPS                                                                         | ¥      | 28.75          | 29.00          | 29.00          | 49.00          | 38.00          | —              | —                | —      | —      | 38.00   | —              | —      |  | —      |  | —       | 38.00   | 42.00   |
| Payout Ratio                                                                | %      | 29.2           | 30.2           | 30.0           | 196.7          | 40.8           | —              | —                | —      | —      | 43.1    | —              | —      |  | —      |  | —       | 42.6    | 40.5    |
| ROE                                                                         | %      | 24.2           | 17.6           | 15.8           | 3.9            | 14.1           | —              | —                | —      | —      | 12.4    | —              | —      |  | —      |  | —       | —       | —       |
| ROA                                                                         | %      | 21.2           | 16.8           | 14.6           | 14.2           | 13.7           | —              | —                | —      | —      | 14.8    | —              | —      |  | —      |  | —       | —       | —       |
| ROIC <sup>*4</sup>                                                          | %      | 14.7           | 12.9           | 11.5           | 11.7           | 11.0           | —              | —                | —      | —      | 11.9    | —              | —      |  | —      |  | —       | —       | —       |
| Capital-to-Asset Ratio                                                      | %      | 67.4           | 68.6           | 68.5           | 70.3           | 74.5           | 74.9           | 75.1             | 76.4   | 75.3   | 75.3    | 77.1           | 79.8   |  | 79.8   |  | —       | —       | —       |
| Receivables Turnover Period                                                 | Day    | 100.7          | 98.3           | 91.5           | 95.8           | 90.7           | —              | —                | —      | —      | 90.5    | —              | —      |  | —      |  | —       | —       | —       |
| Inventory Turnover Period                                                   | Day    | 276.9          | 316.0          | 285.1          | 275.7          | 248.6          | —              | —                | —      | —      | 233.8   | —              | —      |  | —      |  | —       | —       | —       |
| Payables Turnover Period                                                    | Day    | 47.7           | 55.3           | 58.0           | 56.1           | 49.7           | —              | —                | —      | —      | 56.1    | —              | —      |  | —      |  | —       | —       | —       |
| Cash Conversion Cycle                                                       | Day    | 329.8          | 358.9          | 318.6          | 315.4          | 289.7          | —              | —                | —      | —      | 268.2   | —              | —      |  | —      |  | —       | —       | —       |
| Number of Employees (Consolidated)                                          | Person | 906            | 932            | 1,074          | 1,167          | 1,205          | —              | —                | —      | —      | 1,166   | —              | —      |  | —      |  | —       | —       | —       |

\*1 Company shares held by the BIP Trust for directors and Company shares held by the Trust for the Trust-type Employee Shareholding Incentive Plan (E-Ship) are included in treasury shares. (E-Ship terminated on July 29, 2021)

\*2 Values for each Q are for the cumulative period

\*3 EPS after taking into account the stock split. A 1:2 stock split was carried out in Jan. 2018. In light of this, EPS for FY3/2018 is calculated assuming that the stock split took place at the beginning of the previous fiscal year

\*4 Denominator profit is operating profit after tax. After-tax operating profit = operating profit \*(1 - effective tax rate (30.62%))

\*7 Cancellation of treasury shares: May 2019 5 million shares, July 2022 2.5 million shares

(5) Sales by Product

Amounts less than the indicated unit are rounded down.

|                                      |      | FYE March 2018 | FYE March 2019 | FYE March 2020 | FYE March 2021 | FYE March 2022       | FYE March 2023       |        |        |        |         | FYE March 2024 |        |      |       |        |        |       | 2024/3期 |         |         |
|--------------------------------------|------|----------------|----------------|----------------|----------------|----------------------|----------------------|--------|--------|--------|---------|----------------|--------|------|-------|--------|--------|-------|---------|---------|---------|
|                                      |      | FY2017         | FY2018         | FY2019         | FY2020         | FY2021 <sup>*7</sup> | FY2022 <sup>*7</sup> |        |        |        |         | FY2023         |        |      |       |        |        |       | FY2023  |         |         |
|                                      |      | Full YR        | Full YR        | Full YR        | Full YR        | Full YR              | 1Q                   | 2Q     | 3Q     | 4Q     | Full-YR | 1Q             | 2Q     |      |       | 2Q-YTD |        |       | 2Q-YTD  | Full-YR | Full-YR |
|                                      |      | A              | A              | A              | A              | A                    | A                    | A      | A      | A      | A       | A              | A      | YoY  | %     | A      | YoY    | %     | E(Prev) | E(Prev) | E(Rev)  |
| Pacemaker <sup>*6</sup>              | ¥mln | 6,463          | 5,169          | 5,682          | 5,996          | 5,899                | 1,278                | 1,270  | 1,229  | 1,200  | 4,979   | 1,344          | 1,208  | -61  | -4.9  | 2,553  | 3      | 0.2   | —       | 5,011   | 5,006   |
| ICD <sup>*6</sup>                    | ¥mln | 584            | 496            | 5,960          | 7,001          | 6,747                | 1,732                | 1,844  | 1,757  | 1,715  | 7,049   | 1,994          | 1,917  | 73   | 4.0   | 3,911  | 334    | 9.4   | —       | 7,057   | 7,545   |
| Others                               | ¥mln | 200            | 196            | 223            | 250            | 330                  | 83                   | 84     | 99     | 106    | 374     | 108            | 98     | 13   | 16.3  | 206    | 38     | 23.2  | —       | 361     | 387     |
| Cardiac Rhythm Management TTL        | ¥mln | 7,247          | 5,862          | 11,866         | 13,248         | 12,977               | 3,094                | 3,199  | 3,086  | 3,022  | 12,403  | 3,446          | 3,224  | 25   | 0.8   | 6,671  | 377    | 6.0   | —       | 12,431  | 12,939  |
| (CRM YoY)                            | %    | 9.5            | -19.1          | 102.4          | 11.7           | -2.0                 | -6.8                 | -1.8   | -9.1   | 0.6    | -4.4    | 11.4           | 0.8    |      |       | 6.0    |        |       | —       | 0.2     | 4.3     |
| EP Catheter                          | ¥mln | 15,354         | 17,028         | 17,915         | 17,314         | 18,412               | 4,967                | 4,813  | 4,830  | 5,043  | 19,654  | 5,578          | 5,213  | 399  | 8.3   | 10,791 | 1,011  | 10.3  | —       | 20,493  | 21,298  |
| ABL Catheter                         | ¥mln | 1,161          | 1,369          | 1,421          | 1,047          | 1,232                | 321                  | 174    | 272    | 242    | 1,011   | 228            | 187    | 13   | 7.6   | 416    | -79    | -16.1 | —       | 976     | 895     |
| Others                               | ¥mln | 3,848          | 4,662          | 5,358          | 5,501          | 5,455                | 1,374                | 1,360  | 1,359  | 1,532  | 5,626   | 465            | 470    | -890 | -65.4 | 936    | -1,798 | -65.7 | —       | 1,944   | 2,136   |
| EP/Ablation TTL                      | ¥mln | 20,364         | 23,060         | 24,696         | 23,863         | 25,099               | 6,662                | 6,349  | 6,462  | 6,818  | 26,292  | 6,272          | 5,872  | -476 | -7.5  | 12,144 | -867   | -6.7  | —       | 23,414  | 24,329  |
| (EP/ABL YoY)                         | %    | 16.2           | 13.2           | 7.1            | -3.4           | 5.2                  | 7.3                  | 3.7    | -3.5   | 12.3   | 4.8     | -5.9           | -7.5   |      |       | -6.7   |        |       | —       | -10.9   | -7.5    |
| Artificial Heart Valve               | ¥mln | 1,742          | 1,448          | 259            | —              | —                    | —                    | —      | —      | —      | —       | —              | —      | —    | —     | —      | —      | —     | —       | —       | —       |
| Vascular Graft                       | ¥mln | 8,482          | 9,133          | 8,879          | 9,039          | 9,368                | 2,499                | 2,338  | 2,771  | 2,743  | 10,353  | 2,639          | 2,441  | 102  | 4.4   | 5,081  | 243    | 5.0   | —       | 10,681  | 10,812  |
| Neurovascular <sup>*5</sup>          | ¥mln | —              | —              | —              | —              | 12                   | 23                   | 34     | 72     | 99     | 230     | 135            | 218    | 184  | 537.9 | 353    | 295    | 511.6 | —       | 622     | 830     |
| Blood Purification <sup>*1</sup>     | ¥mln | 1,131          | 1,070          | 994            | —              | —                    | —                    | —      | —      | —      | —       | —              | —      | —    | —     | —      | —      | —     | —       | —       | —       |
| Others <sup>*3*5</sup>               | ¥mln | 106            | 77             | 32             | 929            | 748                  | 89                   | 125    | 106    | 102    | 423     | 78             | 133    | 8    | 6.8   | 211    | -2     | -1.3  | —       | 421     | 411     |
| Cardiovascular <sup>*4</sup> TTL     | ¥mln | 11,464         | 11,730         | 10,166         | 9,969          | 10,129               | 2,611                | 2,497  | 2,950  | 2,945  | 11,006  | 2,853          | 2,793  | 295  | 11.8  | 5,646  | 536    | 10.5  | —       | 11,724  | 12,055  |
| (CV YoY)                             | %    | 26.0           | 2.3            | -13.3          | -1.9           | 1.6                  | 14.1                 | 5.0    | 3.0    | 13.5   | 8.6     | 9.2            | 11.8   |      |       | 10.5   |        |       | —       | 6.5     | 9.5     |
| Gastrointestinal                     | ¥mln | 28             | 107            | 132            | 247            | 453                  | 136                  | 153    | 171    | 193    | 654     | 220            | 223    | 70   | 46.2  | 443    | 154    | 53.5  | —       | 1,125   | 982     |
| Others <sup>*3</sup>                 | ¥mln | 3,193          | 4,765          | 4,900          | 3,957          | 2,808                | 463                  | 320    | 338    | 271    | 1,394   | 161            | 63     | -256 | -80.2 | 225    | -558   | -71.3 | —       | 111     | 373     |
| Gastrointestinal <sup>*2*3</sup> TTL | ¥mln | 3,221          | 4,872          | 5,032          | 4,204          | 3,261                | 599                  | 473    | 509    | 465    | 2,048   | 381            | 287    | -186 | -39.3 | 668    | -404   | -37.7 | —       | 1,236   | 1,355   |
| (GI YoY)                             | %    | 15.7           | 51.2           | 3.3            | -16.5          | -22.4                | -24.1                | -37.8  | -44.7  | -41.0  | -37.2   | -36.4          | -39.3  |      |       | -37.7  |        |       | —       | -39.6   | -33.8   |
| Consolidated Net Sales               | ¥mln | 42,298         | 45,525         | 51,761         | 51,286         | 51,469               | 12,969               | 12,519 | 13,009 | 13,251 | 51,750  | 12,954         | 12,177 | -342 | -2.7  | 25,132 | -356   | -1.4  | —       | 48,807  | 50,680  |
| (Consolidated Net Sales YoY)         | %    | 13.8           | 7.6            | 13.7           | -0.9           | 0.4                  | 2.8                  | 0.0    | -6.3   | 6.4    | 0.5     | -0.1           | -2.7   |      |       | -1.4   |        |       | —       | -5.7    | -2.1    |

\*1 Included in "Others" since FYE March 2021  
\*2 Renamed from "Transvascular Intervention" to "Gastrointestinal/PI" since FYE March 2023  
\*3 Renamed from "Gastrointestinal/PI" to "Gastrointestinal" since FYE March 2024 as PI businesses are downsized. Its subcategory "PI-related" is renamed to "Others". Sales of structural heart disease-related is moved to "Cardiovascular, Others" (Reclassifications)  
\*4 Renamed from "Cardiovascular Surgery" to "Cardiovascular" since FYE March 2024  
\*5 Sales of neurovascular-related is moved from "Cardiovascular, Others" to an new independent category of "Cardiovascular, Neurovascular" (Reclassifications)  
\*6 Sales of left ventricular pacing lead is moved from "ICD" to "Pacemaker" since FYE March 2024 (Reclassifications)  
\*7 Reclassifications regarding \*3, \*5, and\*6 are retroactively applied to FY2021 and FY2022.